Key result
Renal endoglin expression was upregulated in patients with chronic allograft dysfunction (p<0.001) and diabetic nephropathy (p<0.05) compared to controls, and correlated with eGFR (p<0.001).
Why the study?
It was hypothesized that endoglin is upregulated in renal interstitial fibrosis and plays a role in the progression of chronic kidney disease.
Observational
p-value: p=<0.001
Endoglin is upregulated in chronic kidney disease and mediates profibrotic responses, suggesting it may serve as a potential therapeutic target to prevent progression to end-stage renal disease.
No takes yet. Share an insight, caveat, or question.
Endoglin upregulation may support its exploration as a CKD therapeutic target; Level 5 data leaves open causal validation in trials.
Gerrits et al. (2022) conducted an observational in Chronic kidney disease. Endoglin expression vs. Control kidneys was evaluated on Renal endoglin expression and correlation with eGFR and interstitial fibrosis (p=<0.001). Renal endoglin expression was upregulated in patients with chronic allograft dysfunction (p<0.001) and diabetic nephropathy (p<0.05) compared to controls, and correlated with eGFR (p<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: